Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study

被引：35
|
作者：
Motzer, Robert [1 ]
Porta, Camillo [2 ,3 ]
Alekseev, Boris [4 ]
Rha, Sun Young [5 ]
Choueiri, Toni K. [6 ]
Mendez-Vidal, Maria Jose [7 ]
Hong, Sung-Hoo [8 ]
Kapoor, Anil [9 ]
Goh, Jeffrey C. [10 ,11 ]
Eto, Masatoshi [12 ]
Bennett, Lee [13 ]
Wang, Jinyi [13 ]
Pan, Jie Janice [14 ]
Saretsky, Todd L. [15 ]
Perini, Rodolfo F. [15 ]
He, Cixin Steven
Mody, Kalgi [14 ]
Cella, David [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy
[3] Univ Pavia, Dept Biomed Sci & Human Oncol, Pavia, Italy
[4] PA Herzen Moscow Oncol Res Inst, Dept Oncourol, Moscow, Russia
[5] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[7] Univ Reina Sofia, Cordoba Hosp, Maimonides Inst Biomed Res, Cordoba, Spain
[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[9] McMaster Univ, Hamilton, ON, Canada
[10] South Brisbane, ICON Res, Brisbane, Qld, Australia
[11] Queensland Univ Technol, Brisbane, Qld, Australia
[12] Kyushu Univ, Fukuoka, Japan
[13] RTI Hlth Solut, Res Triangle Pk, NC USA
[14] Eisai, Nutley, NJ USA
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 06期
关键词：
EQ-5D;
D O I：
10.1016/S1470-2045(22)00212-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Copyright (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码：768 / 780
页数：13
相关论文
共 50 条
  • [1] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomized, phase 3 study
    Motzer, R.
    Porta, C.
    Alekseev, B.
    Rha, S. Y.
    Choueiri, T. K.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Kapoor, A.
    Goh, J. C.
    Eto, M.
    Bennett, L.
    Wang, J.
    Pan, J. J.
    Saretsky, T. L.
    Perini, R. F.
    He, C. S.
    Mody, K.
    Cella, D.
    ONKOUROLOGIYA, 2022, 18 (02): : 39 - 57
  • [2] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Wang, Jinyi
    Pan, Janice
    Asfaw, Alemseged Ayele
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Gruenwald, V.
    Powles, T.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C.
    Motzer, R.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Winquist, E.
    Goh, J. C.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Burgents, J. E.
    Perini, R.
    He, C.
    Okpara, C. E.
    McKenzie, J.
    Choueiri, T. K.
    ONKOUROLOGIYA, 2024, 20 (01): : 24 - 35
  • [5] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
  • [6] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [7] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Mendez Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Merchan, Jaime R.
    Smith, Alan D.
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing Dongyuan
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [9] Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
    Bedke, Jens
    Rini, Brian, I
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Waddell, Tom
    Nosov, Dimitry
    Pouliot, Frederic
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    McDermott, Raymond S.
    Tamada, Satoshi
    Nguyen, Allison Martin
    Wan, Shuyan
    Perini, Rodolfo F.
    Molife, L. Rhoda
    Atkins, Michael B.
    Powles, Thomas
    EUROPEAN UROLOGY, 2022, 82 (04) : 427 - 439
  • [10] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
12345